Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Deborah Bahr"'
Autor:
Emmanuel M. Gabriel, Brian Necela, Deborah Bahr, Sneha Vivekanandhan, Barath Shreeder, Sanjay Bagaria, Keith L. Knutson
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract In this study, we tested a novel approach of “repurposing” a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies a
Externí odkaz:
https://doaj.org/article/15cf9697167549baa914c2e9e20348c7
Autor:
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, Mohammed Ali Ashary, Mizba Baksh, Emmanuel Gabriel
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-21 (2023)
Abstract Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers that individually occur at extremely low frequencies. In
Externí odkaz:
https://doaj.org/article/20004e113736406faabd3a576d95d3fd
Publikováno v:
Journal of Clinical and Translational Science, Vol 4, Pp 6-6 (2020)
OBJECTIVES/GOALS: Our overall objective is to develop a directly observable and reproducible method of enhanced blood flow through tumor vessels (i.e. dynamic control) at the time of systemic treatment delivery. Our central hypothesis is that the dyn
Externí odkaz:
https://doaj.org/article/ba51f9b522454875bffd154a26129dca
Autor:
Keith L. Knutson, Martin J. Cannon, Matthew S. Block, Ellen L. Goode, Kimberly R. Kalli, Joshua Daum, Deborah Bahr, James Krempski, Barath Shreeder, Lavakumar Karyampudi, Purushottam Lamichhane
Expression of PD-1 on BMDCs and T cells after exposure to IL-6 and IL-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41564667fab3bf2525b49273bfdd665b
https://doi.org/10.1158/0008-5472.22416429.v1
https://doi.org/10.1158/0008-5472.22416429.v1
Autor:
Emmanuel M. Gabriel, Brian Necela, Deborah Bahr, Jamie Kaplan, Kristopher Attwood, Keith Knutson
Publikováno v:
Cancer Research. 82:5371-5371
INTRODUCTION: HER2/neu is a potent biomarker for which anti-HER2/neu antibodies offer significant responses. However, many cancers, such as melanoma, have less than 5% expression of HER2/neu. The purpose of this study was to determine whether induced
Autor:
Emmanuel M. Gabriel, Vijay Madamsetty, Deborah Bahr, Jamie Kaplan, Kristopher Attwood, Sanjay Bagaria, Keith Knutson, Debabrata Mukhopadhyay
Publikováno v:
Cancer Research. 82:5071-5071
INTRODUCTION: Intratumoral phenylephrine (α1 vasoconstrictor) combined with chemotherapy has been used for cutaneous malignancies with modest local response. The purpose of this study was to improve the efficacy of intratumoral melphalan using susta
Publikováno v:
Journal of Clinical and Translational Science. 4:6-6
OBJECTIVES/GOALS: Our overall objective is to develop a directly observable and reproducible method of enhanced blood flow through tumor vessels (i.e. dynamic control) at the time of systemic treatment delivery. Our central hypothesis is that the dyn
Autor:
Geraldine Raja, Keith L. Knutson, Yan Luo, Martin J. Cannon, Navnita Dutta, Deborah Bahr, Shreeder Barath
Publikováno v:
Cancer Research. 79:1464-1464
Dendritic cells (DCs) are the most potent antigen-presenting cells which bridges innate and adaptive immunity, but how DC-derived signals regulate and induce T cell lineage choices remains unclear. The p38 MAPK pathway plays an essential role in regu
Autor:
Lavakumar Karyampudi, James Krempski, Keith L. Knutson, Matthew S. Block, Purushottam Lamichhane, Barath Shreeder, Deborah Bahr
Publikováno v:
Clinical Cancer Research. 22:B66-B66
PD-1 and PD-L1 form a major inhibitory axis that acts to suppress tumor-rejecting effector responses. In addition to its expression and inhibitory functions in T and B cells, PD-1 has also been shown to be expressed on and hence impact the functions